Nanomedicine and nanotoxicology: the pros and cons for neurodegeneration and brain cancer
Author
dc.contributor.author
Catalán Figueroa, Johanna
Author
dc.contributor.author
Palma Florez, Sujey
Author
dc.contributor.author
Alvarez, Gonzalo
Author
dc.contributor.author
Fritz, Hans F.
Author
dc.contributor.author
ara, Miguel O.
Author
dc.contributor.author
Morales, Javier O.
Admission date
dc.date.accessioned
2016-01-26T20:31:29Z
Available date
dc.date.available
2016-01-26T20:31:29Z
Publication date
dc.date.issued
2016
Cita de ítem
dc.identifier.citation
Naomedicine Volumen: 11 Número: 2 (2016)
en_US
Identifier
dc.identifier.other
DOI: 10.2217/nnm.15.189
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/136785
General note
dc.description
Artículo de publicación ISI
en_US
General note
dc.description
Sin acceso a texto completo
Abstract
dc.description.abstract
Current strategies for brain diseases are mostly symptomatic and noncurative. Nanotechnology has
the potential to facilitate the transport of drugs across the blood-brain barrier and to enhance their
pharmacokinetic profile. However, to reach clinical application, an understanding of
nanoneurotoxicity in terms of oxidative stress and inflammation is required. Emerging evidence has
also shown that nanoparticles have the ability to alter autophagy, which can induce inflammation
and oxidative stress, or vice versa. These effects may increase neurodegenerative processes
damage, but on the other hand, they may have benefits for brain cancer therapies. In this review,
we emphasize how nanomaterials may induce neurotoxic effects focusing on neurodegeneration,
and how these effects could be exploited toward brain cancer treatment.